Summary of Key Points
As an unprofitable innovative pharmaceutical company, Tianchen Biology's Hong Kong IPO saw 4,470 times oversubscription, setting a record for companies of its size in terms of the amount of capital raised. However, the article warns that behind the market enthusiasm, it is important to distinguish between "certified advantages" and "uncertain risks": while the team has experience, their roles are clearly defined; the company's pipeline consists of both "stable" and "high-risk" projects; financial pressures compel them to commercialize their products quickly; and there are discrepancies in the expectations of both investors and the company regarding success. Ultimately, the true value of the company will be validated by subsequent clinical data and commercialization results.
#### 1. An Experienced Expert as a Brand, but the Actual Drivers are a Young Team
The core team at Tianchen Biology includes two key individuals: 89-year-old Sun Naichao and 43-year-old Liu Heng.
- The Value of Sun Naichao: He is the main inventor of the world's first anti-IgE antibody drug (Omalizumab), which generates annual sales of over $4.4 billion. Although he understands the entire process from drug development to market launch, the prospectus clearly states that his role is merely as a "research and development strategy advisor"—he is not the person who oversees day-to-day operations; rather, he serves as a "symbol of inspiration" and a technical consultant.
- The Role of Liu Heng: He has been involved in the dual approval processes for innovative drugs in China (such as Yilishu) and is well-versed in current Chinese regulatory requirements and clinical advancement procedures. He is the actual operator of the company, leading the team.
Key Reminder: Many investors may be attracted by Sun Naichao's reputation, but it is Liu Heng's team that is doing the actual work. Their experiences complement each other, but their roles are distinct; therefore, the success of the old expert cannot be directly equated with the success of the company's current projects.
#### 2. A Pipeline with Two Approaches: One Steady, One High-Risk
Tianchen Biology has two main pipeline projects: LP-003 (the more certain option) and LP-005 (the more speculative one).
- LP-003: An Improved Version of an Existing Drug with Controllable Risks
LP-003 is an upgraded version of Omalizumab, targeting the same effective mechanism. The key difference is that the dosing interval has been extended from every four weeks to every eight to twelve weeks, making it more convenient for patients. Head-to-head trials have shown better results compared to the control group, and the Phase III trial for seasonal rhinitis has already started enrolling participants. The company expects to apply for market approval in 2026.
Risks: Will the Phase III data be sufficient to justify a higher price than Omalizumab? Can they compete with Novartis (the manufacturer of Omalizumab) in the market? These are known risks that can be addressed if managed properly.
- LP-005: Exploring New Drugs with Uncertain Prospects
LP-005 targets two components of the complement system (C5 and C3b) and is a dual-target inhibitor. This approach is theoretically sound, but there are no successful cases globally yet. Competitors (such as AstraZeneca and Novartis) have typically focused on single-target inhibitors first before moving to dual-target inhibitors. The effectiveness of this approach and potential side effects (e.g., increased risk of infections) are unknown.
Risks: Can these scientific hypotheses be translated into effective drugs? Will LP-005 outperform single-target inhibitors? These are unknown risks with a high probability of failure.
#### 3. IPO Funds Last for Just Over a Year; Immediate Commercialization is Necessary
The financial situation is challenging: the company expects losses of RMB 137 million in 2024 and RMB 176 million in 2025, with net cash outflows for three consecutive years. As of September 2025, the company only has RMB 174 million in cash on hand. The IPO raised approximately HK$1.255 billion, of which 75% will be invested in the two pipeline projects.
Conclusion: These funds will cover the company's needs for about 12 to 18 months. During this period, LP-003 must successfully complete the market application and start generating revenue; otherwise, raising additional funding will become even more difficult due to potential changes in the market environment. This IPO is like a "life-saving card," but the company must use it wisely to "save itself" within its validity period.
#### 4. Disparities in Expectations Between Investors and the Company
The oversubscription reflects investors' belief in a team with successful experience (given that 90% of innovative drug projects fail). However, their expectations are somewhat inflated:
- Investors hope that the team's expertise will lead to a short-term increase in stock prices and quick profits.
- The company aims to establish itself in the global market through differentiation (not by offering lower prices) and to prove that Chinese teams can develop better innovative drugs.
Core Disagreement: Sun Naichao's success with Omalizumab does not guarantee the success of LP-005 or its ability to compete with Novartis. The market's trust is temporary and must be earned through subsequent clinical data, approval results, and sales performance—these are the true indicators of the company's value.
#### In Conclusion
The overwhelming interest in Tianchen Biology's IPO reflects the market's confidence in an experienced team. However, the real test lies ahead: can the company turn potential opportunities into reality and prove its worth through concrete data? This is what will truly determine its future success.
(End of Article)